Word

ENLAZA THERAPEUTICS

Status

Pending

Status Code

688

Status Date

Tuesday, August 20, 2024

Serial Number

97716174

Mark Type

4

Filing Date

Tuesday, December 13, 2022

Published for Opposition

Tuesday, April 30, 2024

Trademark Owner History

Enlaza Therapeutics, Inc. - Owner At Publication

Classifications

5 Pharmaceutical products, preparations, and substances for the treatment of cancer; cancer therapeutics, namely, anti-cancer preparations; novel cancer therapies, namely, pharmaceutical preparations and substances for the treatment of cancer and tumors; biological preparations and substances for the treatment, diagnosis, detection, and prevention of cancer; pharmaceutical products consisting of covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products, namely, covalent protein drugs for the treatment of cancer diseases; pharmaceuticals products consisting of synthetic biology enabled covalent protein biologic for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; pharmaceutical products consisting of covalent protein drugs for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals

1 Reagents for medical research, namely, for therapeutic drug development; antibody reagents for scientific purposes; in-vivo diagnostic reagents for scientific or research use; enzymes for scientific use; cell culture media for use in scientific research for the treatment of cancer and diseases in the nature of infectious diseases, viral diseases, autoimmune diseases, respiratory diseases, diseases of the central nervous system, and fibrotic diseases; active chemical ingredients for use in the manufacture of anti-cancer drugs; laboratory chemicals, namely, an antibody reagent used for the detection of cancerous tumors; antibodies for research use, namely, for therapeutic drug development

42 Research and development in the field of covalent protein biologics; medical and scientific research in the field of cancer treatment and diagnosis; pharmaceutical research and development; research and development of pharmaceuticals and biologicals in the field of cancer therapeutics; research and development in the field of synthetic biology enabled covalent therapeutics and covalent protein drugs; research and development for the purpose of selective covalent modification of proteins; research and development in the field of oncology, namely, development of a biotechnology platform to create covalent protein biologics for treating cancer; research and development in the field of covalent protein drugs, namely, development of a platform technology for identification of small-molecule and biologic therapeutics for treating cancer and targeting tumors; conducting clinical trials for others in the field of cancer therapeutics; biotechnology testing services, namely, testing in the field of recombinant protein production and bioconjugation; research and development services in the field of antibody-drug conjugates, T cells, natural killer (NK) cells, and macrophage engaging antibodies; research and development services for the purpose of antibody engineering, namely, custom design and engineering of antibodies

The English translation of ENLAZA in the mark is to link, bind or connect.
"THERAPEUTICS"

Trademark Events

Dec 16, 2022

New Application Entered

Jan 10, 2023

New Application Office Supplied Data Entered

Sep 16, 2023

Assigned To Examiner

Sep 21, 2023

Non-Final Action Written

Sep 21, 2023

Non-Final Action E-Mailed

Sep 21, 2023

Notification Of Non-Final Action E-Mailed

Nov 28, 2023

Teas Response To Office Action Received

Nov 28, 2023

Correspondence Received In Law Office

Nov 29, 2023

Teas/Email Correspondence Entered

Jan 13, 2024

Non-Final Action Written

Jan 13, 2024

Non-Final Action E-Mailed

Jan 13, 2024

Notification Of Non-Final Action E-Mailed

Mar 22, 2024

Teas/Email Correspondence Entered

Mar 22, 2024

Correspondence Received In Law Office

Mar 22, 2024

Teas Response To Office Action Received

Mar 27, 2024

Approved For Pub - Principal Register

Apr 10, 2024

Notification Of Notice Of Publication E-Mailed

Apr 30, 2024

Official Gazette Publication Confirmation E-Mailed

Apr 30, 2024

Published For Opposition

May 29, 2024

Extension Of Time To Oppose Received

Jul 10, 2024

Extension Of Time To Oppose Process - Terminated

Aug 20, 2024

Noa E-Mailed - Sou Required From Applicant